SB 743921

Drug Profile

SB 743921

Alternative Names: SB-743921; SB-921

Latest Information Update: 21 Oct 2016

Price : $50

At a glance

  • Originator Cytokinetics
  • Class Antineoplastics; Benzopyrans; Small molecules
  • Mechanism of Action KIF11 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Hodgkin's disease; Non-Hodgkin's lymphoma

Most Recent Events

  • 06 Dec 2009 Interim adverse events & efficacy data from the phase I/II CY 2121 trial in Hodgkin's disease & Non-Hodgkin's lymphoma presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009) ,
  • 02 Jun 2009 Interim efficacy & adverse events data from the phase I portion of a phase I/II trial in non-Hodgkin's lymphoma presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO-2009)
  • 24 Dec 2008 SB 743921 is no longer licensed to GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top